Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
Watching Shares Of Edgewise Therapeutics; Traders Circulating Undated Report; Edgewise Therapeutics Launches CIRRUS-HCM Trial To Assess Safety And Effects Of EDG-7500, A Novel Cardiac Sarcomere Modulator For Hypertrophic Cardiomyopathy
Looking Into Cirrus Logic's Recent Short Interest
(CRUS) - Analyzing Cirrus Logic's Short Interest
The Analyst Landscape: 4 Takes On Cirrus Logic
Barclays Maintains Overweight on Cirrus Logic, Raises Price Target to $140